Skip to content

US · ABOS · BIOTECHNOLOGY

Acumen Pharmaceuticals, Inc. (ABOS) intrinsic value and stock valuation

$0.19as of 2026-11-21 · Mkt cap 161.79M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Acumen Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values ABOS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ABOS’s statements →

Acumen Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Newton, MA 02465 acumenpharm.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-121.33M
20192025
Free cash flow
-$-115.63M
20192025
Total equity
$70.4M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-123.83M-$-114.02M-$-61.14M-$-45.24M-$-19.58M
Net income-$-121.33M-$-102.33M-$-52.37M-$-42.86M-$-100.61M
EPSd-$-2M-$-1.71M-$-1.08M-$-1.06M-$-2.63M
Operating cash flow-$-115.54M-$-86.22M-$-43.06M-$-35.15M-$-17.96M
Capital expenditure-$-90K-$-20K-$-20K-$-160K-$-40K
Free cash flow-$-115.63M-$-86.23M-$-43.09M-$-35.31M-$-18M
Total assets$122.8M$239M$310.1M$196.6M$230.3M
Total debt$31.3M$29.7M$28.5M$100K$0.00
Net debt-$-22.68M-$-5.92M-$-38.4M-$-130M-$-122.16M
Total equity$70.4M$181.8M$267M$188.8M$225.2M
Cash and short-term investments$116.9M$171.6M$243.5M$177.6M$194.2M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$12.3M
Gross profit$0.00$0.00$0.00$0.00-$-12.3M
Research and development expenses$104.9M$93.8M$42.3M$32.4M$12.3M
Selling, general and administrative expenses$19M$20.2M$18.8M$12.9M$7.28M
Other expenses$0.00$0.00$0.00$0.00-$-12.3M
Operating expenses$123.8M$114M$61.1M$45.2M$7.28M
Cost and expenses$123.8M$114M$61.1M$45.2M$19.6M
Interest income$7.45M$14.3M$10.8M$2.39M$80K
Interest expense$4.22M$4.07M$580K$0.00$0.00
Depreciation and amortization$180K$180K$180K$170K$0.00
Ebitda-$-116.93M-$-98.08M-$-51.61M-$-42.69M-$-100.6M
Operating income-$-123.83M-$-114.02M-$-61.14M-$-45.24M-$-19.58M
Total other income/expenses, net$2.5M$11.7M$8.77M$2.38M-$-81.02M
Income before tax-$-121.33M-$-102.33M-$-52.37M-$-42.86M-$-100.61M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-121.33M-$-102.33M-$-52.37M-$-42.86M-$-100.61M
Weighted average shares outstanding$60.6M$60M$48.5M$40.6M$38.3M
Weighted average diluted shares outstanding$60.6M$60M$48.6M$40.6M$38.3M
Balance sheet
20252024202320222021
Cash and short-term investments$116.9M$171.6M$243.5M$177.6M$194.2M
Net receivables$620K$0.00$230K$0.00$0.00
Inventory$0.00$160K$0.00$200K$0.00
Total current assets$122.3M$178.3M$246.6M$180.3M$198.7M
Property, plant and equipment, net$240K$340K$500K$270K$40K
Goodwill and intangible assets$30K$0.00$170K$0.00$0.00
Long-term investments$0.00$60M$62.6M$15.8M$31.6M
Total non-current assets$580K$60.7M$63.5M$16.3M$31.7M
Total assets$122.8M$239M$310.1M$196.6M$230.3M
Accounts payable$550K$5.65M$1.38M$1.64M$1.09M
Short-term debt$8.91M$130K$870K$100K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$30M$27.6M$13M$7.81M$5.15M
Long-term debt$22.4M$29.6M$27.6M$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$22.4M$29.6M$30.2M$0.00$0.00
Capital lease obligations$150K$280K$1.15M$100K$0.00
Total liabilities$52.4M$57.2M$43.2M$7.81M$5.15M
Common stock$10K$10K$10K$0.00$0.00
Retained earnings-$-446.46M-$-325.13M-$-222.8M-$-170.43M-$-127.57M
Accumulated other comprehensive income (loss)$80K-$-50K$310K-$-750K-$-230K
Total equity$70.4M$181.8M$267M$188.8M$225.2M
Total investments$62.9M$195.9M$239.2M$63.3M$103.7M
Total debt$31.3M$29.7M$28.5M$100K$0.00
Net debt-$-22.68M-$-5.92M-$-38.4M-$-130M-$-122.16M
Cash flow statement
20252024202320222021
Net income-$-121.33M-$-102.33M-$-52.37M-$-42.86M-$-100.61M
Depreciation and amortization-$-750K$180K$180K$170K$0.00
Stock-based compensation$9.85M$9.63M$6.14M$3.06M$920K
Change in working capital-$-5.12M$11.7M$3.87M$3.99M$300K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-5.09M$4.27M-$-260K$550K$560K
Net cash provided by operating activities-$-115.54M-$-86.22M-$-43.06M-$-35.15M-$-17.96M
Investments in property, plant and equipment-$-90K-$-20K-$-20K-$-160K-$-40K
Acquisitions, net$0.00$0.00$0.00-$-40K$0.00
Net cash used for investing activities$133.9M$48M-$-171.67M$39.2M-$-104.12M
Common stock issued$40K$7.94M$121.9M$3.79M$168.6M
Common stock repurchased-$-70K-$-40K$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-30K$6.93M$151.8M$3.91M$200.5M
Net change in cash$18.4M-$-31.26M-$-62.98M$7.94M$78.4M
Cash at end of period$54.2M$35.9M$67.1M$130.1M$122.2M
Operating cash flow-$-115.54M-$-86.22M-$-43.06M-$-35.15M-$-17.96M
Capital expenditure-$-90K-$-20K-$-20K-$-160K-$-40K
Free cash flow-$-115.63M-$-86.23M-$-43.09M-$-35.31M-$-18M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Acumen Pharmaceuticals, Inc.

        Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.

        CEO
        Daniel J. O'Connell
        Employees
        61
        Beta
        0.34

        Explore

        Frequently asked questions

        What is the intrinsic value of Acumen Pharmaceuticals, Inc. (ABOS)?

        InvestorsCraft does not currently publish an intrinsic value for ABOS. How the IC value is calculated.

        Is ABOS undervalued?

        InvestorsCraft does not publish an undervaluation signal for ABOS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.